story of the week
Rogaratinib vs Chemotherapy for FGFR1/3 mRNA–Positive Locally Advanced or Metastatic Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression
J. Clin. Oncol 2022 Oct 14;[EPub Ahead of Print], CN Sternberg, DP Petrylak, J Bellmunt, H Nishiyama, A Necchi, H Gurney, JL Lee, MS van der Heijden, E Rosenbaum, N Penel, ST Pang, JR Li, X García Del Muro, F Joly, Z Pápai, W Bao, P Ellinghaus, C Lu, M Sierecki, S Coppieters, K Nakajima, TC Ishida, DI QuinnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.